Terbinafine Use in Breastfeeding with History of Fatty Liver
Terbinafine should be avoided in breastfeeding mothers, and is not recommended in patients with a history of fatty liver disease, even if currently stable and otherwise healthy.
Breastfeeding Considerations
The FDA drug label explicitly states that "treatment with terbinafine is not recommended in nursing mothers" 1. This recommendation is based on pharmacokinetic data showing that terbinafine is present in breast milk at a milk-to-plasma ratio of 7:1, meaning the drug concentrates significantly in breast milk 1. While one guideline notes that "terbinafine passes into breast milk, and this could have an effect on a nursing baby" 2, the official FDA labeling takes a more definitive stance against its use during lactation.
The concern is not merely theoretical—the high lipophilicity of terbinafine (which allows excellent tissue penetration for treating fungal infections) also facilitates transfer into breast milk, potentially exposing the infant to substantial drug levels 3.
Fatty Liver Disease Considerations
Systemic terbinafine is explicitly not recommended in patients with active or chronic liver disease 3. The British Association of Dermatologists guidelines (2014) clearly state: "systemic terbinafine is not recommended in patients with active or chronic liver disease" 3. This applies even to non-alcoholic fatty liver disease (NAFLD), which represents chronic liver disease.
Key hepatotoxicity concerns:
- Rare but serious hepatotoxicity has been reported, occurring "usually in patients with pre-existing liver disease" 3
- The FDA drug label warns that "cases of liver failure, some leading to liver transplant or death, have occurred" in individuals both with and without pre-existing liver disease 1
- Baseline liver function tests and complete blood count are recommended in patients with hepatic abnormalities or risk factors 3
- Terbinafine clearance is decreased in patients with severe liver disease 3
Important caveat:
While one case report documented safe use of terbinafine in a patient with stable autoimmune hepatitis 4, this was done with extensive precautions including hepatologist consultation, limiting treatment to <6 weeks, and close monitoring. This represents an exceptional circumstance rather than standard practice, and the patient had a different liver condition than fatty liver disease.
Clinical Algorithm for This Patient
Given both breastfeeding status AND history of fatty liver:
Do not prescribe terbinafine - both conditions represent relative to absolute contraindications
Alternative approaches:
- Delay treatment until after breastfeeding is completed (onychomycosis treatment can be safely postponed)
- Consider topical antifungal therapy alone if the condition requires treatment (though less effective for onychomycosis)
- If the fungal infection is severe and requires systemic therapy, consider griseofulvin as an alternative, though it also has limitations in breastfeeding
If treatment absolutely cannot be delayed:
- Patient must discontinue breastfeeding before starting terbinafine
- Obtain baseline liver function tests and complete blood count
- Consider hepatology consultation given fatty liver history
- Monitor liver enzymes during treatment
- Educate patient on signs of hepatotoxicity (persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, pale stools)
Additional Safety Considerations
Beyond hepatotoxicity and breastfeeding concerns, patients should be counseled about:
- Permanent taste disturbance (rare but can be severe and irreversible) 3, 1
- Smell disturbance including permanent loss of smell 1
- Rare serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) 3, 1
The combination of breastfeeding and pre-existing liver disease makes terbinafine particularly unsuitable for this patient, and alternative management strategies should be pursued.